Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix Limited has announced the application for the quotation of new securities on the Australian Securities Exchange (ASX). This move involves securities that have been issued as a result of options being exercised or other convertible securities being converted. The announcement signifies a strategic step in enhancing the company’s financial operations and market presence, potentially impacting stakeholders by increasing the liquidity and visibility of its securities.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of innovative therapies for unmet medical needs. The company is primarily engaged in the research and development of pharmaceutical products, with a market focus on addressing chronic diseases.
Average Trading Volume: 3,337,251
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$334.3M
For a thorough assessment of DXB stock, go to TipRanks’ Stock Analysis page.